Literature DB >> 11383813

Expression of vascular endothelial growth factor in thoracic sarcomas.

A Iyoda1, K Hiroshima, M Baba, T Fujisawa, T Yusa, H Ohwada.   

Abstract

BACKGROUND: A body of data indicates that vascular endothelial growth factor (VEGF) expression by carcinomas is closely related to the prognosis of carcinomas. However, the relationship between VEGF expression and the prognosis of sarcomas is contradictory.
METHODS: Tissue from 27 cases of thoracic sarcoma was analyzed immunohistochemically for VEGF expression while tumor vascularity was quantified using an antibody directed against endothelial CD34. The relationship between VEGF expression and the prognosis of patients with sarcomas was then evaluated semiquantitatively.
RESULTS: The microvessel count in sarcomas with strong VEGF expression was significantly higher than that in sarcomas with absent or faint VEGF expression. The disease-free survival rates of sarcomas with strong VEGF expression were significantly lower than those of sarcomas with absent or faint VEGF expression. We found that strong VEGF expression impacted on the disease-free survival in multivariate analyses.
CONCLUSIONS: VEGF expression of thoracic sarcomas is directly related to angiogenesis and tumor vascularity, and our findings suggest that strong VEGF expression is an independent prognostic factor in patients with thoracic sarcomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11383813     DOI: 10.1016/s0003-4975(01)02533-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

Review 1.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

2.  Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.

Authors:  Anil Potti; Apar Kishor Ganti; Ketki Tendulkar; Kaley Sholes; Sidharth Chitajallu; Michael Koch; Steven Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-05       Impact factor: 4.553

3.  Targeted therapies in sarcomas: challenging the challenge.

Authors:  Juan Martín Liberal; Laura Lagares-Tena; Miguel Sáinz-Jaspeado; Silvia Mateo-Lozano; Xavier García Del Muro; Oscar M Tirado
Journal:  Sarcoma       Date:  2012-06-03

4.  Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis.

Authors:  Juan Martin-Liberal; Charlotte Benson; Heather McCarty; Khin Thway; Christina Messiou; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2013-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.